X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: HEALTHCAPS INDIA LTD.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing June 02, 2021
Details:
Based on research from Håvard Attramadal's lab at Oslo University Hospital, Tribune is developing a novel drug with a pan-antifibrotic mechanism of action targeting several fibrotic indications including diseases affecting the kidney, lung and liver.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NPH-022
Therapeutic Area: Nephrology Product Name: NPH-022
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Xontogeny, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 12, 2021
Details:
Funds from the financing to be used to advance Nephraegis' lead compound through critical preclinical work. NPH-022 has demonstrated an impressive efficacy and safety profile in rodent models of renal injury, supporting its potential as a breakthrough candidate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cilastatin
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Arch Biopartners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 15, 2021
Details:
Arch secures the commercial rights to the patents around the use of cilastatin that it does not already own. The patents held by Arch and Telara are now unified into one clinical development program to be led by Arch.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
